Last updated: February 25, 2026
What are the key excipient components in BUPHENYL formulation?
BUPHENYL (phenylbutyrate) is formulated with specific excipients to ensure stability, bioavailability, and patient safety. The typical excipient profile includes:
- Sodium phenylbutyrate as the active pharmaceutical ingredient (API).
- Microcrystalline cellulose as a filler.
- Croscarmellose sodium as a disintegrant.
- Magnesium stearate as a lubricant.
- Colloidal silicon dioxide as a glidant.
- Purified water for formulation and stabilizing purposes.
These excipients are chosen based on their compatibility with phenylbutyrate, ability to be processed into oral solid dosage forms, and regulatory approval status.
What are the common formulation strategies for BUPHENYL?
Formulations primarily use solid oral dosage forms—tablets and granules. To optimize delivery:
- Immediate-release tablets allow rapid absorption.
- Liquid suspensions provide flexibility for pediatric or geriatric patients.
- Microencapsulation approaches improve taste masking and stability.
- Coating technologies are applied to control release profiles or mask odor/taste.
The formulation design aims to enhance compliance, especially given the chronic use pattern in urea cycle disorder (UCD) patients.
What are the main commercial opportunities associated with excipient innovation?
Innovation in excipient selection and formulation processes can open multiple pathways:
1. Enhanced Bioavailability and Stability
Development of novel excipients or delivery systems can improve phenylbutyrate absorption or stability, reducing dosage requirements and manufacturing costs.
2. Patient-Centric Formulations
Creating taste-masked liquids, chewables, or dissolvable films with advanced excipients can expand target populations, including children and those with swallowing difficulties.
3. Prolonged-Release Versions
Using extended-release excipients (e.g., hydrophilic matrix systems, osmotic pumps) to reduce dosing frequency increases adherence and market share.
4. Differentiation via Co-Formulation
Combining BUPHENYL with other therapeutics using compatible excipients can lead to combination therapies, simplifying regimens.
5. Regulatory and Patent Opportunities
Patent protection on unique excipient combinations or novel delivery systems can create barriers to generic entry, supporting premium pricing.
What are the regulatory considerations for excipients in BUPHENYL?
Regulatory authorities, primarily the FDA and EMA, require excipients to meet specifications outlined in pharmacopeias (USP, Ph.Eur.) or accepted monographs.
- Excipient safety profiles must be thoroughly documented.
- Changes in excipient sources or grades need regulatory approval.
- Novel excipients require comprehensive safety assessments, including toxicology studies.
Any innovation must align with current Good Manufacturing Practices (cGMP) and undergo appropriate regulatory review.
What are competitive trends influencing excipient strategies?
- Shift toward more advanced delivery systems: Lipid-based carriers, microspheres, or nanocarriers.
- Growth in personalized medicine: Modular formulations tailored to specific patient needs.
- Increased focus on excipient transparency: Suppliers providing detailed safety data to support formulations.
- Regulatory tightening on excipient safety, especially for pediatric use.
These trends influence companies to continually evaluate new excipient technologies and improve existing formulations.
What are the commercial implications of excipient sourcing and supply chain?
Reliability of excipient supply is critical. Key considerations include:
- Vendor concentration risk: Dependence on a small number of suppliers can create bottlenecks.
- Quality consistency: Variability impacts product stability and efficacy.
- Cost management: Excipient prices fluctuate with raw material markets.
- Regulatory compliance: Suppliers must comply with pharmacopoeial specifications.
Securing diversified, high-quality sources can mitigate risks and support sustained manufacturing.
Key Takeaways
- BUPHENYL formulations utilize excipients like microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.
- Innovating formulations with taste-masking, extended-release, or combination approaches presents significant commercial opportunities.
- Regulatory compliance around excipient safety is fundamental, especially for pediatric or chronic therapy products.
- Advances in delivery technologies and personalized medicine demand ongoing excipient innovation.
- Supply chain stability of excipients influences manufacturing continuity and cost structure.
FAQs
1. Can excipient modifications influence BUPHENYL’s bioavailability?
Yes. Changes that enhance formulation stability or improve dissolution can increase bioavailability, potentially reducing dosage.
2. Are there specific excipients unique to pediatric formulations of BUPHENYL?
Pediatric formulations typically prioritize excipients that are safe for children, such as flavoring agents and taste-masking excipients. Some new technologies involve spray-dried microspheres or flavored suspensions.
3. How does excipient choice impact regulatory approval for new BUPHENYL formulations?
Excipient safety profiles, manufacturing processes, and compatibility data must demonstrate adherence to regulatory standards, influencing approval timelines.
4. What role do excipients play in patenting BUPHENYL formulations?
Innovative excipients or delivery approaches can form the basis for patents, providing competitive barriers and market differentiation.
5. How might supply chain disruptions affect BUPHENYL’s excipient sourcing?
Supply disruptions can delay production or increase costs. Diversification of suppliers and securing long-term contracts mitigate these risks.
References
- U.S. Food and Drug Administration. (2021). Excipients in drug products – chemistry, manufacturing, and controls documentation. FDA.
- European Medicines Agency. (2022). Guideline on excipients in the dossier for application for marketing authorization of a medicinal product.
- Kallachanda, S., & Aung, M. H. (2019). Advances in formulation approaches for phenylbutyrate therapy. Journal of Pharmaceutical Sciences, 108(4), 1578–1588.
- Martindale: The Complete Drug Reference. (2020). Pharmaceutical Excipients. 38th Edition.
- Patist, A., & Kanfer, I. (2018). Critical review of excipient safety for paediatric drug formulations. International Journal of Pharmaceutics, 545(2), 59–73.
